Supplementary Figure 3: The immune cell profile in miR25/93 overexpression tumors.

(a) The levels for miR25/93 in either control tumors or miR25/93 overexpressing tumors. (b) FACS analysis showed accumulation of CD11b⁺ Ly6G⁻ Ly6C^high monocytic MDSC in miR25/93 overexpressing tumors, as compared with control tumors. E0771 cells were used for generating miR25/93 overexpressing tumors. (c and d) The percentage of CD11b⁺ F4/80⁺ TAM or CD11b⁺ Ly6G⁺ Ly6C^low granulocytic MDSC inmiR25/93 overexpressing tumors vs. control tumors.(e and f)The immune cell profile for tumor infiltrating CD4⁺ T cells or CD8⁺ T cells inmiR25/93 overexpressing tumors vs. control tumors. (g) Gene expression analysis in whole tumor specimen for selected genes responsible for anti-tumor immunity. (h) The elevated levels of tumor promoting factors in miR25/93 overexpressing tumors as compared to control tumors. For panel a, the data are presented as means ± SD (n = 3 independent experiments). Asterisk indicates P < 0.05, compared with controls. For panels b–d, control: n = 4 tumors from 4 different animals, miR25/93: n = 4 tumors from 4 different animals. For panels e,f, control: n = 10 tumors from 10 different animals, miR25/93: n = 13 tumors from 13 different animals. For panels g,h, n = 8 tumors from 8 different animals. Data shown in b–h represent the mean of the above-indicated sample numbers. Samples were compared using two-tailed Student’s t test. ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001, ns not significant.